Ai2 BEMA Presentation

1
Curtis Dobson
Business Development
Markets Applications
Management
Further Growth
Science Technology
2
Overview

• Ai2 aims to become a significant player in the
  anti-infectives market

Ai2 Core Business is the identification of unmet
anti-infective needs in the medical devices market
Principal Focus is addressing those needs for a
range of devices including catheters, wound
dressings and ophthalmic devices
3
Business Development
BBSRC SBRI grant (220k) to set up capability to
manufacture biomaterials in house
European Community grant ( 2.8m) to test new
peptides as medical device coatings and
therapeutics for resistant infection
Awarded Bionow North West Biotech Project of the
Year 2004 and North West Biotech Start-up of
the Year 2005
Undertaking paid development work with three
major US corporations term sheets received for
specific applications
Company owned by Manchester University,
Manchester Technology Fund, and academic founders
Very low cash burn (approx 34k / month)
4
Management
Senior Management Role Experience
Mr Kevin DSilva Chairman (business
mentor/networking) 25 Dr Curtis
Dobson CEO (Ai2 founder)
15 Dr Phil Morgan Director 17 Mr
Richard Young Director (MD of Manchester Tech
Fund) 22
Business Development Dr Gordon
Barker Business Manager UMIP 9
SAB and consultants Dr Anand Dutta SAB
peptide-chemistry 35 Dr Rein Ulijn
SAB biomaterials 9 Professor Keith
Crutcher SAB host responses 30 Dr Phil
Morgan SAB medical devices - clinical 17
5
Science Technology
Human serum lipoprotein
HIV
Dobson and Itzhaki, Neurobiology of Aging,
1999 Dobson et al, Trends in Microbiology, 2003
6
Science Technology
Extended wear lenses are now manufactured from
silicone hydrogels exhibiting better biotolerance
than previously used biopolymers.
Nonetheless they remain prone to infection.
Peptide-treated lenses resistant to Pseudomonas
infection
Untreated
Treated
7
Science Technology
Key Benefits
Infection Control
Biocompatibility
8
Science Technology
Other Benefits
Sterilisable, e.g. can be autoclaved
Physically stable
Readily manufactured at GMP grade in suitable
quantities, at a cost-effective price
Extremely large range of molecules with slightly
differing activities
Simply and efficiently adhere irreversibly to a
range of relevant surfaces
9
Markets Applications
Product Pipeline Key Markets
Risk
Time to market
10
Markets Applications
Coatings
Solutions
Therapeutics
11
Markets Applications
External / disposable Catheters (urinary)
Contact lenses Contraceptives (barrier)
Endotracheal tubes Wound dressings
Medical Device Coatings
Internal / surgical Breast implants
Orthopaedics Intraocular lenses Endovascular
catheters Cochlear implants Sutures Stents
12
Further Growth
Confirmation of activity against resistant
organisms, and in preventing development of
biofilm
Confirmation of safety, including that for more
demanding therapeutic applications
Novel Peptide Against Resistant Infection NPARI
13
Further Growth
2007
2009
2008
2010
MD1
L
Proof of Concept
Joint Development
Royalty Revenue
MD2
Royalty Revenue
Joint Development
L
Proof of Concept
MD3
Proof of Concept
L
Joint Development
P1
Proof of Concept
L
J D

Required Resource Secured
12
7
9
20
L
14
Summary
Ai2 currently focused on meeting unmet
anti-infective need in medical device markets
Ai2 has secured substantial grant funding to
allow extensive in house refinement of its
technology
Ai2 offers powerful anti-infective action with
biocompatibility, in a format easily applied to a
range of devices
Application of Ai2 technology to medical device
products could provide one of the most exciting
advances in this sector in recent years
15
(No Transcript)